4175 related articles for article (PubMed ID: 11826235)
21. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
[TBL] [Abstract][Full Text] [Related]
22. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.
Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A
AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661
[TBL] [Abstract][Full Text] [Related]
23. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
[TBL] [Abstract][Full Text] [Related]
24. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.
Wamalwa DC; Obimbo EM; Farquhar C; Richardson BA; Mbori-Ngacha DA; Inwani I; Benki-Nugent S; John-Stewart G
BMC Pediatr; 2010 May; 10():33. PubMed ID: 20482796
[TBL] [Abstract][Full Text] [Related]
25. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
26. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Scherpbier HJ; Bekker V; van Leth F; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2006 Mar; 117(3):e528-36. PubMed ID: 16481448
[TBL] [Abstract][Full Text] [Related]
27. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.
Chaix ML; Rouet F; Kouakoussui KA; Laguide R; Fassinou P; Montcho C; Blanche S; Rouzioux C; Msellati P
Pediatr Infect Dis J; 2005 Dec; 24(12):1072-6. PubMed ID: 16371868
[TBL] [Abstract][Full Text] [Related]
28. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
[TBL] [Abstract][Full Text] [Related]
29. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.
Evans TG; Bonnez W; Soucier HR; Fitzgerald T; Gibbons DC; Reichman RC
Antiviral Res; 1998 Oct; 39(3):163-73. PubMed ID: 9833957
[TBL] [Abstract][Full Text] [Related]
30. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children.
Wamalwa DC; Farquhar C; Obimbo EM; Selig S; Mbori-Ngacha DA; Richardson BA; Overbaugh J; Emery S; Wariua G; Gichuhi C; Bosire R; John-Stewart G
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):311-7. PubMed ID: 17356470
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Puthanakit T; Oberdorfer A; Akarathum N; Kanjanavanit S; Wannarit P; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2005 Jul; 41(1):100-7. PubMed ID: 15937769
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status.
van Rossum AM; Scherpbier HJ; van Lochem EG; Pakker NG; Slieker WA; Wolthers KC; Roos MT; Kuijpers JH; Hooijkaas H; Hartwig NG; Geelen SP; Wolfs TF; Lange JM; Miedema F; de Groot R;
AIDS; 2001 Nov; 15(17):2267-75. PubMed ID: 11698700
[TBL] [Abstract][Full Text] [Related]
33. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
34. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.
Rutstein RM; Gebo KA; Flynn PM; Fleishman JA; Sharp VL; Siberry GK; Spector SA
Med Care; 2005 Sep; 43(9 Suppl):III15-22. PubMed ID: 16116305
[TBL] [Abstract][Full Text] [Related]
35. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
36. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
37. Association of Body Composition and Other Clinical Factors with Incomplete Immune Response after Highly Active Antiretroviral Therapy.
Sun PT; Yu W; Li TS; Lin Q; Guo FP; Zhou XH; Du GY; Xu Y; Guan WM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):459-464. PubMed ID: 28877821
[TBL] [Abstract][Full Text] [Related]
38. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.
Chadwick EG; Rodman JH; Britto P; Powell C; Palumbo P; Luzuriaga K; Hughes M; Abrams EJ; Flynn PM; Borkowsky W; Yogev R;
Pediatr Infect Dis J; 2005 Sep; 24(9):793-800. PubMed ID: 16148846
[TBL] [Abstract][Full Text] [Related]
39. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
[TBL] [Abstract][Full Text] [Related]
40. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
